Phase 3 Studies of Vaccines

The Vaccine Book

Volumn , Issue , 2003, Pages 95-117

  Clemens, John D ^a   Koo, Hye Won ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0038673790     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012107258-2/50009-3     Document Type: Chapter

References (50)

1. National Institute of Allergy and Infectious Diseases Accelerated Development of Vaccines: The Jordan Report 2000.
2. Byar D.P., Simon R.M., Friedewald W.T., et al. Randomized clinical trials: Perspective on some recent ideas. New England J. Medicine 1976, 295:74-80.
3. Bailar J. Introduction. Clinical Trials: Issues and Approaches 1983, Marcel Dekker, New York. S.H. Shapiro, T.A. Louis (Eds.).
4. Chalmers T.C. The control of bias in clinical trials. Clinical Trials: Issues and Approaches 1983, 115. Marcel Dekker, New York. S.H. Shapiro, T.A. Louis (Eds.).
5. Greenwood M., Yule G. The statistics of anti-typhoid and anti-cholera inoculations. Proc. R. Soc. Med. 1915, 8:113.
6. Clemens J., Harris J., Sack D., et al. Field trial of oral cholera vaccines in Bangladesh: Results of one year of folow-up. J. Infect. Dis. 1988, 158:60-69.
7. Clemens J., Horwitz R. Longitudinal evaluation of therapy. Biomedicine 1984, 38:440-443.
8. Levine R.J., Lebacqz K. Ethical considerations in clinical trials. Clin. Pharmacol. Ther. 1979, 25:728-741.
9. Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: I. Introduction and design. Br. J. Cancer 1976, 34:585-612.
10. Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br. J. Cancer 1977, 35:1-39.
11. Feinstein A.R. Clinical biostatistics: XXII. The role of randomization in sampling, testing, allocation, and credulous idolatry (part 1). Clin. Pharmacol. Ther. 1973, 14:601-615.
12. Feinstein A.R. Clinical biostatistics: XXIII. The role of randomization in sampling, testing, allocation, and credulous idolatry (part 2). Clin. Pharmacol. Ther. 1973, 14:898-915.
13. Feinstein A.R. Clinical biostatistics: XXIV. The role of randomization in sampling, testing, allocation, and credulous idolatry (conclusion). Clin. Pharmacol. Ther. 1973, 14:1035-1051.
14. Meier P. Statistical analysis of clinical trials. Clinical Trials: Issues and Approaches 1983, 115. Marcel Dekker, New York. S.H. Shapiro, T.A. Louis (Eds.).
15. Clemens J.D., Chuong J.J., Feinstein A.R. The BCG controversy: A methodological and statistical reappraisal. J. Am. Med. Assoc. 1983, 249:2362-2369.
16. Halloran M., Haber M., Longini I., et al. Direct and indirect effects in vaccine efficacy and effectiveness. Am. J. Epidemiol. 1991, 33:323-331.
17. Fine P. Herd immunity: History, theory, practice. Epidemiol. Rev. 1993, 15:265-302.
18. Clemens J., Brenner R., Rao M., et al. Evaluating new vaccines for developing countries: Efficacy or effectiveness?. J. Am. Med. Assoc. 1996, 275:390-397.
19. Struchiner C., Halloran M., Robins J., Spielman A. The behaviour of common measure of association used to asses a vaccination programme under complex disease transmission patterns-A computer simulation study of malaria vaccines. Int. J. Epidemiol. 1990, 19:187-196.
20. Moulton L., O'Brien K., Koeberger R., et al. Design of a group-randomized Streptococcus pneumoniae vaccine trial. Controlled Clin. Trials 2001, 22f:438-452.
21. Szmuness W., Stevens C., Harley E., et al. Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high risk population in the United States. New England J. Medicine 1980, 303:833-841.
22. Santiago L. Large HIV vaccine trial begins. GMHC Treat Issues 1998, 12:1-5.
23. Institute of Medicine Diseases of importance in developing countries. New Vaccine Development. Establishing Priorities 1986, Vol. II:241. National Academy Press, Washington, DC.
24. Donner A. Approaches to sample size estimation in the design of clinical trials-A review. Stat. Med. 1984, 3:199-214.
25. Armitage P. Statistical Methods in Medical Research 1971, Blackwell, Oxford, UK.
26. Glass R.I., Backer S, Huq M.I., et al. Endemic cholera in rural Bangladesh, 1966-80. Am. J. Epidemiol. 1977, 116:959-970.
27. Clemens J.D., Sack D.A., van Loon F.P.L., et al. Non-participation as a determinant of adverse health outcomes in a field trial of oral cholera vaccines. Am. J. Epidemiol. 1992, 135:865-874.
28. Clemens J., Sack D., Harris J., et al. Field trial of oral cholera vaccines in Bangladesh: Results from long-term follow-up. Lancet 1990, 335:270-273.
29. Lachin J. Statistical elements of the randomized clinical trial. The Randomized Clinical Trial and Therapeutic Decisions 1982, 82. Marcel Dekker, New York. N. Tygstrup, J. Lachin, E. Juhl (Eds.).
30. Feinstein A.R., Landis J.R. The role of prognostic stratification in preventing bias permitted by random allocation of treatment. J. Chron Dis. 1976, 29:277-284.
31. Pocock S. Clinical Trials: A Practical Approach 1983, Wiley, Chichester, UK.
32. Levine M.M., Ferreccio C., Black R.E., et al. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987, 1:1049-1052.
33. Donner A., Donald A. Analysis of data arising from a stratified design with the cluster as the unit of randomization. Stat. Med. 1987, 6:43-52.
34. Clemens J.D., Sack D.A., Harris J.R., et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986, 2:124-127.
35. Clemens J., Sack D., Rao M., et al. Evidence that inactivated oral cholera vaccines both prevents and mitigates Vibrio cholerae 01 infections in a cholera-endemic area. J. Infect. Dis. 1992, 166:1029-1034.
36. Great Britain Medical Research Council BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early life. Br. Med. J. 1956, 1:413.
37. Brown J.A., Stone M.M., Sutherland I. BCG vaccination of children against leprosy: First results of a trial in Uganda. Br. Med. J. 1966, 1:7-14.
38. Simanjuntak C.H., Paleologo F.P., Punjabi N.H., et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991, 338:1055-1059.
39. Fleiss J. Statistics for Rates and Proportions 1981, 193. Wiley, New York. 2nd ed.
40. Jacobsen R., Adegbenro A., Pankratz V., Poland G. Adverse events and vaccination-The lack of power and predictability of infrequent events in a pre-licensure study. Vaccine 2001, 19:2428-2433.
41. Expanded Programme on Immunization Safety of high titre measles vaccine. Weekly Epidemiol. Record 1992, 67:357-362.
42. Peltola H., Kayhty H., Virtanen M., Makela P. Prevention of H. influenzae type b bacteremic infection with a capsular polysaccharide vaccine. New Engl. J. Med. 1984, 310:1566-1569.
43. Kallings L., Olin P., Storsaeter J. Protective effect of 2 acellular pertussis vaccines in a double-blind, placebo-controlled trial. Lakartidningen 1988, 85:1994-1996.
44. Feinstein A.R. Clinical Epidemiology: The Architecture of Clinical Research 1985, Saunders, Philadelphia.
45. Smith P., Morrow R. Field Trials of Health Interventions in Developing Countries: A Toolbox 1996, MacMillan, London.
46. Ward J., Brenneman G., Letson G., et al. Limited efficacy of a Haemophilus influenzae type B conjugate vaccine in Alaskan Native infants. New England J. Medicine 1990, 323:1393-1401.
47. Angell M. The ethics of clinical research in the Third World. New England J. Medicine 1997, 337:847-849.
48. Chen R., De Stefano F., Davis R., et al. The Vaccine Safety Datalink: Immunization research in health maintenance organizations in the USA. Bull. WHO 2000, 78:186-194.
49. Clemens J. Evaluating vaccine safety before and after licensure. Bull. WHO 2000, 78:218-219.
50. International Conference on Harmonisation. E6: Guideline for Good Clinical Practice 1996.